Based on these results, a Phase I trial was initiated where the treatment of one patient with advanced pancreatic cancer with anti-mesothelin resulted in almost complete tumor disappearance 240 days post IV infusion of 7 × 19 CAR-T cells [182]. The gene discussed is MSLN; the disease is neoplasm.